CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

31 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

22 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

09 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

27 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

01 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

29 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

22 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

11 Jul 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

27 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

12 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

21 May 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

08 May 2024 15:15:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

30 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

16 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

02 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

18 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

12 Mar 2024 15:05:00 By Nasdaq GlobeNewswire